|
Vaccine Detail
Vi Capsular Polysaccharide Typhoid Vaccine |
Vaccine Information |
- Vaccine Name: Vi Capsular Polysaccharide Typhoid Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007055
- Type: Live attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Preparation: Typherix was supplied as a 0.5-ml dose of vaccine containing 25 μg of the Vi capsular polysaccharide of Salmonella typhi (Ochiai et al., 2014; Plotkin and Bouveret-Le, 1995).
- Description: A live attenuated bacteria injectable vaccine used to prevent typhoid, which is caused by Salmonella typhi (NCT03294564; NCIT_C97127).
|
Host Response |
|
References |
NCIT_C97127: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97127]
NCT03294564: Cognitive, Emotional, and Neural Responses to Acute Inflammation [https://clinicaltrials.gov/ct2/show/NCT03294564]
Ochiai et al., 2014: Ochiai RL, Khan MI, Soofi SB, Sur D, Kanungo S, You YA, Habib MA, Sahito SM, Manna B, Dutta S, Acosta CJ, Ali M, Bhattacharya SK, Bhutta ZA, Clemens JD. Immune responses to Vi capsular polysaccharide typhoid vaccine in children 2 to 16 years old in Karachi, Pakistan, and Kolkata, India. Clinical and vaccine immunology : CVI. 2014; 21(5); 661-666. [PubMed: 24599532].
Plotkin and Bouveret-Le, 1995: Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Archives of internal medicine. 1995; 155(21); 2293-2299. [PubMed: 7487253].
|
|